Improvements in Migraine-specific Quality of Life Questionnaire (MSQ) Domain Scores with Fremanezumab and Galcanezumab in Patients with Multiple Prior Migraine Preventive Treatment Failures: A Network Meta-analysis
Author(s)
Mu F1, Driessen MT2, Cohen J3, Wang Y1, Ayyagari R1
1Analysis Group, Boston, MA, USA, 2Teva Pharmaceuticals, Amsterdam, Netherlands, 3Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA
OBJECTIVES Head-to-head randomized, controlled trials(RCTs) comparing efficacy of monoclonal antibodies targeting the calcitonin gene-related peptide(CGRP) pathway for preventive migraine treatment are not available. This network meta-analysis(NMA) assessed relative efficacy of fremanezumab and galcanezumab on Migraine-specific Quality of Life Questionnaire(MSQ) scores in patients with chronic or episodic migraine(CM or EM) with multiple prior treatment failures. METHODS The MSQ evaluates impact of migraine on 3 health-related quality-of-life domains: role-function-restrictive(RFR), role function-preventive(RFP), and emotional function(EF). A systematic literature review(SLR) was conducted to identify placebo-controlled RCT evaluating effects of fremanezumab quarterly(675mg) and monthly(225mg) or galcanezumab(120mg) on MSQ in CM or EM patients with 2-4 and ≥3 prior preventive failures. A NMA within a Bayesian framework examined change from baseline in MSQ domain scores in 2 subgroups (2-4 and ≥3 prior failures). Data presented here are for CM and EM patients combined. RESULTS The SLR identified 2 RCTs in CM and EM patients; the NMA evaluated changes in MSQ scores from baseline over weeks 9-12 (based on available data). Median increases in RFR scores were statistically significantly greater for fremanezumab quarterly, fremanezumab monthly, and galcanezumab, respectively, versus placebo in the 2-4 prior failures subgroup (8.7 points[95% credible interval(CrI):4.88,12.55], 10.59[6.78,14.42], and 12.52[8.72,16.27]) and ≥3 prior failures subgroup (10.74[5.19,16.37], 11.84[6.33,17.30], and 15.28[7.72,22.98]). Median increases in RFR scores were similar with no statistically significant differences for galcanezumab versus fremanezumab quarterly and monthly, respectively, in the 2-4 prior failures subgroup (3.84[95% CrI: −1.52,9.20] and 1.93[−3.47,7.22]) and ≥3 prior failures subgroup (4.53[−4.84,13.96] and 3.43[−5.78,12.78]). Similar results were shown for the RFP and EF scores in the 2-4 prior failures subgroup. CONCLUSIONS Both fremanezumab and galanezumab showed statistically significant and clinically meaningful increases in MSQ scores versus placebo in migraine patients with multiple prior preventive failures. Across all 3 MSQ domains, no statistically significant differences were noted between fremanezumab and galcanezumab.
Conference/Value in Health Info
2021-05, ISPOR 2021, Montreal, Canada
Value in Health, Volume 24, Issue 5, S1 (May 2021)
Code
PND3
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Biologics and Biosimilars, Neurological Disorders